2010
Escitalopram versus placebo in the treatment of dysthymic disorder
Hellerstein DJ, Batchelder ST, Hyler S, Arnaout B, Toba C, Benga I, Gangure D. Escitalopram versus placebo in the treatment of dysthymic disorder. International Clinical Psychopharmacology 2010, 25: 143-148. PMID: 21811192, DOI: 10.1097/yic.0b013e328333c35e.Peer-Reviewed Original ResearchConceptsHamilton Depression Rating ScaleDysthymic disorderGlobal assessmentSelective serotonin reuptake inhibitorsClinical Global Impressions-SeveritySuperiority of escitalopramPercentage of respondersPlacebo-treated individualsSerotonin reuptake inhibitorsDepression Rating ScaleStructured Clinical InterviewPercentage of participantsLarger study sampleItem total scoresSocial Adjustment ScaleAcute efficacyEscitalopram doseHDRS-24Active medicationReuptake inhibitorsWeek 12Inclusion criteriaSecondary measuresEscitalopramClinical Interview
2009
Sheehan Suicidality Tracking Scale (Sheehan-STS): Preliminary Results from a Multicenter Clinical Trial in Generalized Anxiety Disorder.
Coric V, Stock EG, Pultz J, Marcus R, Sheehan DV. Sheehan Suicidality Tracking Scale (Sheehan-STS): Preliminary Results from a Multicenter Clinical Trial in Generalized Anxiety Disorder. Innov Clin Neurosci 2009, 6: 26-31. PMID: 19724740, PMCID: PMC2719443.Peer-Reviewed Original ResearchClinical trialsHAM-D itemsGeneralized anxiety disorderSheehan Suicidality Tracking ScaleSuicidal thoughtsWeek 8Suicidal ideationCorticotropin-releasing factor antagonistAnxiety disordersTreatment-emergent suicidal ideationActive comparator studiesExploratory outcome measuresClinician-Administered Rating ScaleMulticenter clinical trialStudy time pointsScale total scoreLarger study sampleComparator studiesStudy protocolMean changeOutcome measuresWeek 4Prospective assessmentFactor antagonistsClinical care
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply